What is the Paul-Ehrlich-Institut?

The Paul-Ehrlich-Institut (PEI) is Germany's federal institute for vaccines and biomedicines within the Federal Ministry of Health's remit. It combines regulatory responsibilities with research. Its product remit particularly includes specified vaccines and biological medicines.

Activities include scientific assessment, medicine safety, particular authorization procedures and official batch release. The function relevant to a case depends on the product and regulatory procedure.

What is its role in development and authorization?

PEI assesses submissions within its responsibilities and participates in European procedures. In centralized EU authorization, scientific assessment takes place within the EMA network and the European Commission makes the legal authorization decision. PEI therefore does not independently grant every European vaccine authorization.

Clinical trials have their own regulatory and ethical requirements. Scientific advice can support development, but it replaces neither subsequent assessment nor the necessary evidence of quality, efficacy and safety.

What does official batch release mean?

Specified medicines require official release of individual production batches in addition to product authorization. Assessment considers matters such as compliance with specifications and the relevant manufacturing and testing documentation.

PEI can perform its own tests or recognize appropriate results from other official laboratories in the European network. Its batch-testing FAQ explains the procedure. Each vaccine batch used in Germany does not necessarily undergo a complete repeat investigation in PEI's own laboratory.

Which resources help communication teams?

Safety communications, product lists and official notices are important sources for current information. An adverse-reaction report initially records a suspicion rather than automatically establishing causation.

Marketing teams need accurate descriptions of regulatory responsibility, approved product information and safety context. An authority's assessment or batch release should not be presented as a promotional endorsement. New safety information belongs in coordinated internal updating processes.

Conclusion: Scientific assessment and continuing oversight

PEI contributes to medicine safety through several regulatory and scientific functions. Authorization, batch release and pharmacovigilance serve different purposes. None guarantees complete absence of risk; continuing benefit-risk assessment remains essential.